Intensity Bets on Reverse Split to Maintain Nasdaq Listing

SHELTON, Conn. – February 13, 2026 – Intensity Therapeutics, a late-stage biotechnology company developing novel cancer treatments, announced a significant financial maneuver today aimed at preserving its standing on the Nasdaq stock exchange. The company will execute a 1-for-25 reverse stock split, a move intended to boost its flagging share price above the exchange's minimum requirement.

The announcement, however, was met with immediate investor apprehension. Shares of Intensity (Nasdaq: INTS) tumbled more than 26% in trading, reflecting a common market skepticism toward such corporate actions, which are often perceived as a last resort for companies facing financial pressure. The move places a renewed focus on the company's ability to translate its promising clinical pipeline into tangible value, a challenge that now unfolds under the increased scrutiny of a post-split market.

A Necessary Move to Avoid Delisting

The decision to consolidate its shares comes as a direct response to Nasdaq's stringent listing requirements. The exchange mandates that a company's stock must maintain a minimum bid price of $1.00 per share. For weeks, Intensity's stock has languished far below this threshold, trading in a range of $0.27 to $0.37, triggering a non-compliance notice and the threat of delisting.

Effective after market close on February 18, 2026, the reverse split will automatically convert every twenty-five shares of common stock into a single share. This will drastically reduce the number of outstanding shares from approximately 63.3 million to about 2.5 million. While this action will mechanically increase the per-share price—for example, a $0.30 stock would theoretically trade at $7.50 post-split—it does not alter the company's fundamental market capitalization or intrinsic value.

This type of financial engineering is a well-worn path for clinical-stage biotech firms, which often burn through capital for years during lengthy research and development phases without generating revenue. Maintaining a Nasdaq listing is crucial for these companies, as it provides access to a broader pool of institutional investors and facilitates future capital raises. However, regulators have recently tightened the rules. Under new SEC-approved Nasdaq provisions, companies that use a reverse split to regain compliance but see their stock fall below the $1.00 threshold again within a year may face immediate delisting without another grace period, raising the stakes for Intensity to achieve sustained performance.

Investor Skepticism and a Volatile Market

The sharp decline in Intensity's stock price following the announcement underscores a persistent challenge: reverse splits are often interpreted as a sign of weakness rather than strength. While the move addresses a technical compliance issue, it does little to change the underlying business fundamentals that contributed to the low stock price in the first place.

Historically, the performance of biotech companies following a reverse split is mixed. For some, it is a temporary fix, with share prices often eroding back toward pre-split levels if the company fails to deliver on key clinical or commercial milestones. The market's reaction reflects this uncertainty, with investors weighing the risk of continued decline against the potential upside of the company's scientific platform.

Intensity's financial health presents a classic biotech paradox. The company's balance sheet shows minimal debt and a strong liquidity position, bolstered by a capital raise of over $20 million in 2025 that extended its cash runway into the second quarter of 2027. Yet, it continues to operate at a significant loss, with an earnings per share (EPS) of -0.63 and a substantial negative free cash flow yield. This reliance on external funding to fuel its operations makes its access to public markets, and therefore its Nasdaq listing, critically important. Analyst sentiment remains divided, with some maintaining a "Moderate Buy" rating based on the long-term potential of its pipeline, while others point to the weak financial metrics and cash burn as reasons for a more "Neutral" stance.

The Core Value: A Promising Cancer Therapy Pipeline

Beyond the financial mechanics of the stock split lies the true driver of Intensity Therapeutics' potential value: its lead drug candidate, INT230-6. The company is pioneering a new approach to cancer treatment focused on direct intratumoral injection. INT230-6 is not a typical systemic chemotherapy; instead, it is designed to be injected directly into a tumor, where it saturates the cancerous tissue and kills cells from within.

The drug candidate leverages Intensity's proprietary DfuseRx℠ platform, which combines two proven anti-cancer agents, cisplatin and vinblastine, with a unique molecule that enhances their diffusion throughout the tumor's dense, high-fat environment. This localized attack is designed to achieve two primary goals: first, to destroy the tumor directly with high concentrations of cytotoxic agents while minimizing systemic side effects, and second, to trigger a robust, systemic immune response. By causing the tumor to break down, INT230-6 releases a flood of cancer-specific antigens, effectively training the patient's own immune system to recognize and attack similar cancer cells elsewhere in the body—a phenomenon known as an abscopal effect.

Data from its completed Phase 1/2 clinical trial, which enrolled over 200 patients with various metastatic cancers, has been encouraging. Results published in the peer-reviewed journal eBioMedicine in October 2025 showed a 75% disease control rate. Notably, in a cohort of patients with advanced metastatic sarcoma, a notoriously difficult-to-treat cancer, treatment with INT230-6 resulted in a median overall survival of 21.3 months. The study also documented evidence of the desired abscopal effect in at least 20% of patients who received a sufficient dose, suggesting the therapy could have benefits far beyond the injected tumor.

Navigating Clinical Hurdles and Financial Headwinds

With promising early-stage data in hand, Intensity is pushing INT230-6 into late-stage trials, but the path forward is not without its challenges. The company's ambitious clinical program is directly intertwined with its financial stability, a link underscored by recent developments.

The global Phase 3 INVINCIBLE-3 study, which is testing INT230-6 as a monotherapy for soft tissue sarcoma, had to pause enrollment due to prior funding constraints. With its recently strengthened balance sheet, Intensity plans to restart patient recruitment and site activations during 2026, but the delay highlights the precarious nature of funding for clinical-stage biotechs. The trial's primary endpoint is overall survival, a high bar that, if met, could be transformative for patients and the company.

Simultaneously, the INVINCIBLE-4 study, a Phase 2 trial in early-stage triple-negative breast cancer, is also navigating the typical hurdles of drug development. Following observations of localized skin irritation in some participants, the company is amending the study protocol to adjust dosing volumes. Enrollment is expected to reinitiate in 2026 for the 61-patient study. Early data has shown a favorable safety profile compared to standard chemotherapy, but the final results on pathological complete response will be a key indicator of the drug's efficacy in this setting.

Ultimately, the reverse stock split is a strategic, if unpopular, tool to ensure Intensity Therapeutics has the financial footing and market access needed to see these critical trials through. While the immediate market reaction has been negative, the company's long-term trajectory will not be defined by this financial restructuring. Instead, its future rests on the scientific and clinical validation of INT230-6 and its potential to shift the paradigm in cancer treatment.